Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host

What this study is about

By obtaining clinical specimens from participants with triple negative breast cancer (TNBC), colorectal cancer (CRC), high grade serous ovarian cancer (HGSOC), and other select tumor types to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with personalized cancer treatment options

Who can join (things the study team will check)

✅ You may be able to join if…

• Age > 18 years.
• Patient diagnosis must be categorized as either (I) OR (II) OR (III) OR (IV): (I) Histologically confirmed Triple Negative Breast Cancer by Institutional and American Society of Clinical Oncology (ASCO)/Cancer of American Pathologists (CAP) guidelines, either: OR (II) Histologically-confirmed Stage IV colorectal cancer treated with ≤ 1 line of systemic therapy in the metastatic setting, either: OR (III) Histologically-confirmed advanced High Grade Serous Ovarian Cancer, either: OR (IV) Histologically confirmed solid tumor not meeting criteria for (I), (II) or (III) above, for which evaluation of investigational therapies is of particular interest or where clinical need exists, at the discretion of the PI
  • Stage IV (metastatic) disease that has not been treated with systemic therapy in the metastatic setting or
  • Stage I to III (non-metastatic) with residual mass by clinical exam and/or breast imaging following anthracycline + taxane-containing neoadjuvant chemotherapy
  • Undergoing surgical resection of liver metastases or
  • With metastatic lesions amenable to biopsy
  • Recurrent disease with a life expectancy of at least 12 months or
  • Stage III or IV with residual disease following neoadjuvant chemotherapy, or at risk of high recurrence
• Disease amenable to biopsy or surgery for tissue procurement
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Willingness and ability of patient to provide signed voluntary informed consent.

🚫 You may not be able to join if…

• Clinically significant hepatic, renal, cardiac or other organ dysfunction likely to limit participation in clinical trials.
• Known brain metastasis
• Any condition that could interfere with a patient's ability to provide informed consent such as dementia or severe cognitive impairment.
• Any contraindication to undergoing a biopsy procedure.

Where this trial is running

• Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Who to contact

David Cescon, MD · 416-946-2245 · Dave.Cescon@uhn.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT02732860.